The role of negative symptoms and cognitive dysfunction in schizophrenia outcome
The DOI matches its Crossref record.
Abstract
Schizophrenia is a lifelong illness, with symptoms beginning in late adolescence/early adulthood and persisting throughout the rest of the patient's life. Positive psychotic symptoms may fluctuate during the course of the illness, but negative symptoms, especially primary negative symptoms, and cognitive dysfunction are relatively constant. The negative symptoms of schizophrenia are both primary (associated with the illness) and secondary (due to depression, neuroleptic-induced parkinsonism or acute psychosis). While secondary negative symptoms may be reduced by treating the causative agent, primary negative symptoms are viewed as enduring, persisting between psychotic episodes. Conventional antipsychotics treat the positive symptoms of schizophrenia, but they have little effect on primary negative and cognitive symptoms. Primary negative symptoms are often associated with poor premorbid function, the male sex, and low IQ (Intelligence Quotient). In addition, most studies find that negative symptoms are associated with a poor overall outcome. Several studies, including our own, have suggested that primary negative symptoms are functionally localized to the frontal and parietal cortices. These kinds of data raise the possibility that primary negative symptoms may have a pathophysiological basis distinct from positive psychosis. Cognitive impairment also appears to be a relatively independent aspect of schizophrenia. Impairment may be evident in a subtle form from early childhood, and often precedes the development of psychotic symptoms. Additional impairment accrues with the onset of psychotic illness with little evidence, in the vast majority of cases, of progression over the course of the illness. Cognitive impairment is only modestly related to psychotic symptom severity and type. However, the extent, and perhaps specific types of cognitive impairment, appear to be predictive of functional outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
Stone, J. M., Morrison, P. D., & Pilowsky, L. S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073126 · Cited by 348
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Snyder, G. L., Vanover, K. E., Zhu, H., Miller, D. B., O’Callaghan, J. P., Tomesch, J., Li, P., Zhang, Q., Krishnan, V., Hendrick, J. P., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3704-1 · Cited by 289
Uhlhaas, P. J., & Singer, W. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.019 · Cited by 243
Waltz, J. A., Schweitzer, J. B., Gold, J. M., Kurup, P. K., Ross, T. J., Jo Salmeron, B., Rose, E. J., McClure, S. M., & Stein, E. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.214 · Cited by 186
Self-citation
Metadata
- Authors
- Tamminga, C. A., Buchanan, R. W., & Gold, J. M.
- Venue
- International Clinical Psychopharmacology
- Published
- 1998-03
- Volume
- 13
- Pages
- S21-S26
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2047887517
- Cited by
- 162
- References
- 0
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. https://app.cochat.ai/papers/10.1097/00004850-199803003-00004
- The paper
- Tamminga, C. A., Buchanan, R. W., & Gold, J. M. (1998). The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199803003-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.